Pasireotide is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option, among other approved uses. MedsAcross supplies Pasireotide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
Source: US FDA prescribing information
SIGNIFOR LAR is an injectable cyclohexapeptide, somatostatin analog. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). There are 5 known human somatostatin receptor subtypes: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Somatostatin analogs bind to SSTRs with different potencies. Pasireotide binds with high affinity to 4 of the 5 SSTRs. Table 4 – Binding Affinities of Somatostatin (SRIF-14) and Pasireotide to the Five Human SSTR Subtypes (SSTR 1-5) Results are the mean + SEM of IC 50 values expressed as nmol/l (nM). Compound SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 Somatostatin (SRIF-14) 0.93 ± 0.12 0.15 ± 0.02 0.56 ± 0.17 1.5 ± 0.4 0.29 ± Pasireotide 9.3 ± 0.1 1.0 ± 0.1 1.5 ± 0.3 > 100 0.16 ± 0.01
Source: US FDA prescribing information
Evaluate fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), liver enzyme tests, electrocardiogram (ECG), serum magnesium, and serum potassium prior to starting. Optimize glucose control in patients with poorly controlled diabetes mellitus prior to starting. Must be administered by a health care professional only by intramuscular injection in the right or left gluteus immediately after reconstitution. Initial Dose: Acromegaly: The initial dose is 40 mg by intramuscular injection once every 4 weeks (every 28 days). Cushing's Disease: The initial dose is 10 mg by intramuscular injection once every 4 weeks (every 28 days). Adjust dose based on response and tolerability. Patients with Hepatic Impairment: Child-Pugh B: Acromegaly: Recommended initial dose is 20 mg once every 4 weeks and maximum dose is 40 mg once every 4 weeks.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Hyperglycemia, Diabetes, and Ketoacidosis: Sometimes severe. Monitor glucose levels as clinically appropriate during therapy. Monitor glucose levels more frequently in the months that follow initiation or discontinuation of SIGNIFOR LAR therapy and following SIGNIFOR LAR dose adjustment. Use anti-diabetic treatment if indicated.If ketoacidosis is suspected, discontinue SIGNIFOR LAR and promptly evaluate and treat the patient. Bradycardia and QT Prolongation: Use with caution in at-risk patients, evaluate ECG and electrolytes prior to dosing and periodically while on treatment. Liver Test Elevations: Evaluate liver enzyme tests prior to and during treatment. Cholelithiasis and Complications of Cholelithiasis: Monitor periodically. Discontinue if complications of cholelithiasis are suspected.
Source: US FDA prescribing information
Clinically significant adverse reactions that appear in other sections of the labeling include: Hyperglycemia, Diabetes, and Ketoacidosis Bradycardia and QT Prolongation Liver Test Elevations Cholelithiasis and Complications of Cholelithiasis Pituitary Hormone Deficiency(ies) Steatorrhea and Malabsorption of Dietary Fats Adverse drug reactions associated with SIGNIFOR LAR and occurring in ≥ 20% of patients were diarrhea, cholelithiasis, hyperglycemia, and diabetes mellitus.
Source: US FDA prescribing information
Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. Cyclosporine: Consider additional monitoring. Bromocriptine: Consider bromocriptine dose reduction.
Source: US FDA prescribing information
Store at 2°C to 8°C (36°F-46°F). Do not freeze. SIGNIFOR LAR should be stored at refrigerated temperatures between 2°C to 8°C (36°F-46°F) until the time of use. Do not freeze. SIGNIFOR LAR drug product kit should remain at room temperature for a minimum of 30 minutes before reconstitution, but should not exceed 24 hours at room temperature.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Pasireotide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Signifor LAR kit Cold chain | Recordati Rare Diseases | US FDA | Available on request |
| Signifor 0.3 mg/1 mL injectionSubcutaneous | Recordati Rare Diseases | US FDA | Available on request |
| Signifor 0.6 mg/1 mL injectionSubcutaneous | Recordati Rare Diseases | US FDA | Available on request |
| Signifor 0.9 mg/1 mL injectionSubcutaneous | Recordati Rare Diseases | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Pasireotide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Pasireotide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Pasireotide, including Signifor, Signifor LAR.
Yes. The US FDA first approved Pasireotide on 15 December 2014, according to Drugs@FDA.
Yes. Pasireotide has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Pasireotide must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Pasireotide is classified under ATC code H01CB05 (Pasireotide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.